Date: 26-Aug-2019

China approves AstraZeneca drug to treat anaemia in CKD patients

AstraZeneca has announced that its partner FibroGen (China) Medical Technology Development Co., Ltd. (FibroGen China) has received marketing authorisation for roxadustat in China for the treatment of anaemia caused by chronic kidney disease (CKD) in non-dialysis-dependent (NDD) patients.